- Significant Series A Funding: Aqemia secures a substantial €60m in Series A funding, aiming to advance its AI and quantum-inspired drug discovery platform, expediting the development of new drugs targeting various diseases.
- Innovative Drug Discovery Technology: Leveraging generative AI and quantum algorithms, Aqemia accelerates the identification of drug candidates, significantly reducing the traditional timeline from discovery to pre-clinical phases.
- Strategic Industry Collaborations and Growth: With strategic partnerships like the $140m deal with Sanofi and collaboration with Servier, Aqemia aims to expand its drug discovery pipeline, planning to grow its workforce and enter clinical trials by 2025.
Eksentricity 